S. M. Imanalieva
S. M. Imanalieva has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Bayan Sagindykova
South Kazakhstan Medical Academy
1 shared publication - G. B. Shoinbayeva
Южно-Казахстанская медицинская академия
1 shared publication - I. E. Kaukhova
Санкт-Петербургский химико-фармацевтический университет
1 shared publication - Murat Zulpidinovich Ashirov
School of Pharmacy, Asfendiyarov Kazakh National Medical University, 94, Tole Bi Str., 050012 Almaty, Kazakhstan
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Non-state educational institution "Kazakh-Russian Medical University" in Actual Problems of Theoretical and Clinical Medicine
- Vol. 50 (4)
RESEARCH ON THE SAFETY AND ACTIVITY OF MELOXICAM TABLETS FOR CHILDREN
The development of safe and effective anti-inflammatory dosage forms for children is one of the most important areas of modern pharmaceutical science. Among nonsteroidal anti-inflammatory drugs, meloxicam is among the most commonly used substances in clinical practice. Objective. To study the preclinical toxicity and anti-inflammatory activity of meloxicam tablets for children (coated, prolonged effects, special dose). Methods and materials: acute toxicity in animals was determined, as well as an assessment of specific pharmacological activity in models of histamine-induced and carrageenan aseptic inflammation. Study results: The study showed that Meloxicam tablets for children are non-toxic and have greater anti-inflammatory activity than the comparison drug. The study on the specific activity of Meloxicam 3.75 mg tablets for children + cyanocobalamin 0.002 mg demonstrated their high anti-inflammatory activity in experimental aseptic inflammation models. This indicates an increased anti-inflammatory effect of meloxicam when combined with cyanocobalamin. Conclusion: the results showed that the anti–inflammatory activity of the studied drug, meloxicam children’s tablets, is higher than that of the comparative drug meloxicam.
- 1 January 2025
- Published by Non-state educational institution "Kazakh-Russian Medical University" in Actual Problems of Theoretical and Clinical Medicine
- Vol. 50 (4)
Open AccessRESEARCH ON THE SAFETY AND ACTIVITY OF MELOXICAM TABLETS FOR CHILDREN
The development of safe and effective anti-inflammatory dosage forms for children is one of the most important areas of modern pharmaceutical science. Among nonsteroidal anti-inflammatory drugs, meloxicam is among the most commonly used substances in clinical practice. Objective. To study the preclinical toxicity and anti-inflammatory activity of meloxicam tablets for children (coated, prolonged effects, special dose). Methods and materials: acute toxicity in animals was determined, as well as an assessment of specific pharmacological activity in models of histamine-induced and carrageenan aseptic inflammation. Study results: The study showed that Meloxicam tablets for children are non-toxic and have greater anti-inflammatory activity than the comparison drug. The study on the specific activity of Meloxicam 3.75 mg tablets for children + cyanocobalamin 0.002 mg demonstrated their high anti-inflammatory activity in experimental aseptic inflammation models. This indicates an increased anti-inflammatory effect of meloxicam when combined with cyanocobalamin. Conclusion: the results showed that the anti–inflammatory activity of the studied drug, meloxicam children’s tablets, is higher than that of the comparative drug meloxicam.